AR068552A1 - Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas - Google Patents

Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas

Info

Publication number
AR068552A1
AR068552A1 ARP080104172A ARP080104172A AR068552A1 AR 068552 A1 AR068552 A1 AR 068552A1 AR P080104172 A ARP080104172 A AR P080104172A AR P080104172 A ARP080104172 A AR P080104172A AR 068552 A1 AR068552 A1 AR 068552A1
Authority
AR
Argentina
Prior art keywords
polypeptides
phage
omegamru
cells
microbial cells
Prior art date
Application number
ARP080104172A
Other languages
English (en)
Original Assignee
Pastoral Greenhouse Gas Res Lt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pastoral Greenhouse Gas Res Lt filed Critical Pastoral Greenhouse Gas Res Lt
Publication of AR068552A1 publication Critical patent/AR068552A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/20—Reduction of greenhouse gas [GHG] emissions in agriculture, e.g. CO2
    • Y02P60/22—Methane [CH4], e.g. from rice paddies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)

Abstract

Composiciones y métodos para la administracion de moléculas inhibidoras en células microbianas, en particular, células metanogenas. Específicamente, se refiere al omegamru fago recientemente identificado, que incluye la induccion del fago, partículas del fago, y el genoma del fago, y también polipéptidos del fago, así como también polinucleotidos que codifican estos polipéptidos. También se refiere a vectores de expresion y células huésped para la produccion de estos polipéptidos, a métodos para detectar, apuntar, e inhibir células microbianas, especialmente células metanogenas, utilizando el fago revelado, polipéptidos, polinucleotidos, vectores de expresion, y células huésped, también posee composiciones farmacéuticas que comprenden el fago omegamru.
ARP080104172A 2007-09-25 2008-09-25 Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas AR068552A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97510407P 2007-09-25 2007-09-25
US98984007P 2007-11-22 2007-11-22
US98984107P 2007-11-22 2007-11-22

Publications (1)

Publication Number Publication Date
AR068552A1 true AR068552A1 (es) 2009-11-18

Family

ID=40511642

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP080104173A AR068553A1 (es) 2007-09-25 2008-09-25 Vacunas y componentes de vacuna para la inhibicion de celulas microbianas
ARP080104171A AR068551A1 (es) 2007-09-25 2008-09-25 Peptidos y polipeptidos permeabilizantes celulares para celulas microbianas
ARP080104172A AR068552A1 (es) 2007-09-25 2008-09-25 Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP080104173A AR068553A1 (es) 2007-09-25 2008-09-25 Vacunas y componentes de vacuna para la inhibicion de celulas microbianas
ARP080104171A AR068551A1 (es) 2007-09-25 2008-09-25 Peptidos y polipeptidos permeabilizantes celulares para celulas microbianas

Country Status (17)

Country Link
US (7) US8586709B2 (es)
EP (5) EP3936516A1 (es)
JP (5) JP6067209B2 (es)
CN (4) CN101932595B (es)
AR (3) AR068553A1 (es)
AU (4) AU2008304018A1 (es)
BR (5) BRPI0817312B1 (es)
CA (3) CA2700129C (es)
CL (3) CL2008002859A1 (es)
DK (3) DK2203466T3 (es)
ES (3) ES2587595T3 (es)
MX (3) MX2010003321A (es)
NZ (1) NZ745324A (es)
RU (1) RU2528854C2 (es)
UY (3) UY31361A1 (es)
WO (3) WO2009041830A2 (es)
ZA (1) ZA201001933B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2203466T3 (en) * 2007-09-25 2016-07-25 Pastoral Greenhouse Gas Res Ltd Cell permeabilizing peptides and polypeptides for microbial cells
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
EP3363896A1 (en) * 2009-06-26 2018-08-22 Lysando AG Antimicrobial agents
SI2445515T1 (sl) 2009-06-26 2016-08-31 Lysando Ag Antimikrobna sredstva
AU2010287069B2 (en) 2009-08-27 2016-07-07 Pastoral Greenhouse Gas Research Ltd Complete genome sequence of the methanogen Methanobrevibacter ruminantium
SG184836A1 (en) * 2010-04-27 2012-11-29 Lysando Ag Method of reducing biofilms
ES2802253T3 (es) * 2012-09-19 2021-01-18 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10119133B2 (en) 2013-03-15 2018-11-06 The General Hospital Corporation Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
WO2015070083A1 (en) 2013-11-07 2015-05-14 Editas Medicine,Inc. CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
CN107406838A (zh) * 2014-11-06 2017-11-28 纳幕尔杜邦公司 Rna引导的内切核酸酶向细胞中的肽介导的递送
CN104789675A (zh) * 2015-04-15 2015-07-22 江苏师范大学 一种检测荷斯坦奶牛瘤胃微生物的方法
US11845928B2 (en) * 2015-05-04 2023-12-19 Tsinghua University Methods and kits for fragmenting DNA
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
MX2019000621A (es) * 2016-07-14 2019-08-01 Basf Se Medio de fermentacion que comprende agente quelante.
CN110431237A (zh) * 2016-12-29 2019-11-08 伊鲁米纳公司 用于在细胞区室中正交接近和标签化生物分子的分析系统
WO2018126499A1 (zh) * 2017-01-05 2018-07-12 深圳迈瑞生物医疗电子股份有限公司 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物
US10745439B2 (en) * 2017-03-20 2020-08-18 Regents Of The University Of Minnesota Kinase substrates and methods of use thereof
US20190233816A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
KR20240038811A (ko) * 2018-03-19 2024-03-25 리제너론 파마슈티칼스 인코포레이티드 CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
CN113677359A (zh) * 2018-11-14 2021-11-19 鲁比克治疗股份有限公司 Cd25抗体
CN109627301B (zh) * 2019-02-18 2022-08-05 浙江新银象生物工程有限公司 Nisin固体稳定剂开发及应用
CN112143747B (zh) * 2020-09-09 2022-09-13 昆明理工大学 一种噬菌体裂解酶及其基因、基因重组表达载体与应用
MX2023006678A (es) 2020-12-08 2023-08-22 Ruminant Biotech Corp Ltd Mejoras en los dispositivos y métodos para suministrar sustancias a los animales.
CN112961217B (zh) * 2021-03-19 2022-11-08 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN113121705B (zh) * 2021-04-19 2023-03-24 成都英普博集生物科技有限公司 用于制备短肽混合物的融合蛋白、目的多肽、短肽混合物的制备方法及应用
WO2024015366A1 (en) * 2022-07-11 2024-01-18 Arkea Bio Corp. Compositions and methods for reducing methane emissions in ruminant populations
CN115938486B (zh) * 2022-12-06 2023-11-10 内蒙古农业大学 基于图神经网络的抗菌性乳酸菌株筛选方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159861A (en) * 1875-02-16 Improvement in brooms
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
EP0150186A1 (fr) * 1983-05-03 1985-08-07 S.S.M. International Chemical Company Limited Composition a activite pharmaceutique amelioree et utilisation decelle-ci pour des usages veterinaires
GB8815968D0 (en) * 1988-07-05 1988-08-10 Pfizer Ltd Veterinary devices
JPH05219927A (ja) * 1992-02-14 1993-08-31 Gumma Pref Gov 飼料の混合装置及び混合飼料の製造方法
JP3651915B2 (ja) * 1993-06-30 2005-05-25 財団法人神奈川科学技術アカデミー シグナル配列ペプチドをコードするｄｎａ断片の探索法及びそのためのベクター
DE69433645T2 (de) * 1993-10-19 2005-03-10 Commonwealth Scientific And Industrial Research Organisation Methode zur verbesserung der nahrungsverwertung von wiederkäuern oder wiederkäuer-ähnlichen tieren
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
NZ278977A (en) 1994-01-20 1997-03-24 Pastoral Agric Res Inst Nz Ltd Sustained release bolus for ruminants
CA2181693C (en) 1994-01-20 2006-09-19 Rex Munday Device for administration of beneficial materials to ruminants
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
AUPN353695A0 (en) 1995-06-14 1995-07-06 Commonwealth Scientific And Industrial Research Organisation Immunogenic preparation and method for improving the productivity of ruminant animals
US6503729B1 (en) * 1996-08-22 2003-01-07 The Board Of Trustees Of The University Of Illinois Selected polynucleotide and polypeptide sequences of the methanogenic archaeon, methanococcus jannashii
US5985907A (en) * 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2003038109A2 (en) 2001-09-18 2003-05-08 The Board Of Regents Of The University Of Nebraska Method for the inhibition of methanogenesis
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
AU2003222249A1 (en) 2002-03-04 2003-09-22 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
SE523209C2 (sv) * 2002-05-14 2004-04-06 Akzo Nobel Nv Förfarande för att reducera metanbildningen från matspjälkningsaktiviteter hos djur
EP1861490A4 (en) 2005-03-23 2010-11-17 Univ St Louis USE OF ARRAYS TO MODULATE NUTRIENT CAPTURE FUNCTIONS BY THE GASTROINTESTINAL MICROBIOTE
DK2203466T3 (en) * 2007-09-25 2016-07-25 Pastoral Greenhouse Gas Res Ltd Cell permeabilizing peptides and polypeptides for microbial cells
CN101434924A (zh) * 2008-12-17 2009-05-20 中南大学 一种分离严格厌氧产甲烷古菌的方法
AU2010287069B2 (en) * 2009-08-27 2016-07-07 Pastoral Greenhouse Gas Research Ltd Complete genome sequence of the methanogen Methanobrevibacter ruminantium
CN101864362B (zh) * 2010-05-19 2012-05-09 江苏加德绿色能源有限公司 一种复合微生物菌剂及其应用
DE102011119230B4 (de) * 2011-11-23 2013-07-11 Audi Ag Kraftwagen-Blinkleuchte und Verfahren zum Betreiben einer Blinkleuchte
WO2014100726A2 (en) * 2012-12-21 2014-06-26 Danisco Us Inc. Production of isoprene, isoprenoid, and isoprenoid precursors using an alternative lower mevalonate pathway

Also Published As

Publication number Publication date
CA2700164A1 (en) 2009-04-02
WO2009041831A1 (en) 2009-04-02
DK2203466T3 (en) 2016-07-25
EP2203466B1 (en) 2016-04-06
DK2203467T3 (en) 2017-03-27
AR068551A1 (es) 2009-11-18
JP5552053B2 (ja) 2014-07-16
EP2203466A4 (en) 2011-04-13
BR122020023381B1 (pt) 2021-09-08
WO2009041830A2 (en) 2009-04-02
JP5558356B2 (ja) 2014-07-23
CN107129524B (zh) 2023-11-21
DK3327030T3 (da) 2021-10-04
BRPI0817312B1 (pt) 2018-05-29
CL2008002861A1 (es) 2009-03-06
WO2009041832A2 (en) 2009-04-02
CN102015755A (zh) 2011-04-13
EP2203470A4 (en) 2011-04-13
JP2017046704A (ja) 2017-03-09
BRPI0817299A8 (pt) 2019-01-29
US10995120B2 (en) 2021-05-04
US8586709B2 (en) 2013-11-19
US11926647B2 (en) 2024-03-12
BRPI0817299A2 (pt) 2015-06-16
CL2008002860A1 (es) 2009-06-05
UY31360A1 (es) 2009-04-30
US20100221185A1 (en) 2010-09-02
WO2009041830A9 (en) 2009-08-27
CA2700129A1 (en) 2009-04-02
US20200325180A1 (en) 2020-10-15
AU2014210649B2 (en) 2016-09-08
US20210332087A1 (en) 2021-10-28
EP2203467B1 (en) 2016-12-14
CN101918431B (zh) 2014-10-08
WO2009041832A9 (en) 2009-10-22
WO2009041832A3 (en) 2009-06-11
EP2203467A1 (en) 2010-07-07
US10590170B2 (en) 2020-03-17
EP2203467A4 (en) 2011-04-13
AU2014210649A1 (en) 2014-09-04
CA2700162C (en) 2018-08-14
EP2203466A2 (en) 2010-07-07
US20140220636A1 (en) 2014-08-07
ES2625144T3 (es) 2017-07-18
WO2009041831A9 (en) 2009-11-05
US20100209998A1 (en) 2010-08-19
CL2008002859A1 (es) 2009-03-06
CA2700129C (en) 2021-07-20
ES2587595T3 (es) 2016-10-25
JP2010539927A (ja) 2010-12-24
JP2010539928A (ja) 2010-12-24
US9296789B2 (en) 2016-03-29
AU2008304018A1 (en) 2009-04-02
BRPI0817312A2 (pt) 2015-03-17
EP3936516A1 (en) 2022-01-12
AR068553A1 (es) 2009-11-18
AU2008304019A1 (en) 2009-04-02
JP2015042166A (ja) 2015-03-05
RU2010116163A (ru) 2011-11-10
EP3327030B1 (en) 2021-07-21
US20100209999A1 (en) 2010-08-19
JP2010539926A (ja) 2010-12-24
CA2700164C (en) 2018-05-29
MX2010003319A (es) 2010-09-10
BR122021010737B1 (pt) 2021-09-21
RU2528854C2 (ru) 2014-09-20
BR122021010729B1 (pt) 2022-02-15
AU2008305846A1 (en) 2009-04-02
CN107129524A (zh) 2017-09-05
WO2009041830A3 (en) 2009-07-02
MX340736B (es) 2016-07-22
CN101918431A (zh) 2010-12-15
US8592556B2 (en) 2013-11-26
NZ745324A (en) 2023-02-24
UY31359A1 (es) 2009-04-30
US20170342112A1 (en) 2017-11-30
EP2203470A2 (en) 2010-07-07
MX2010003328A (es) 2010-08-16
JP6067209B2 (ja) 2017-01-25
UY31361A1 (es) 2009-04-30
CA2700162A1 (en) 2009-04-02
ES2895908T3 (es) 2022-02-23
MX2010003321A (es) 2010-08-03
CN101932595B (zh) 2016-02-10
ZA201001933B (en) 2013-10-30
EP3327030A1 (en) 2018-05-30
CN101932595A (zh) 2010-12-29

Similar Documents

Publication Publication Date Title
AR068552A1 (es) Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas
CL2015001353A1 (es) Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.
BR112018001660A2 (pt) células exterminadoras naturais e linhagens de células exterminadoras naturais modificadas possuindo citotoxicidade aumentada
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
CL2015001790A1 (es) Compuestos derivados de 3,4-dihidroisoquinolina sustituidos, inhibidores de prmt5; composicion farmaceutica; kit farmaceutico; metodo de inhibicion de prmt5; metodo para tratar la expresion de un gen; metodo para alterar la transcripcion; metodo de tratamiento de un trastorno tal como cancer, diabetes y obesisdad, entre otros.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
EA201290295A1 (ru) Специфичные к рецептору меланокортина-1 линейные пептиды
CR20190319A (es) ANTICUERPOS CONTRA EL INHIBIDOR DEL ACTIVADOR DE PLASMINÓGENO TIPO 1 (PAI-1) Y USOS DE LOS MISMOS (Divisional 2016-0117)
UY34643A (es) Derivados de 5-alquinilo piridina como inhibidores de apoptosis,composiciones farmacéuticas y sus usos como miméticos smac
DOP2013000209A (es) Inhibidores de glucosilceramida sintasa
CO6761351A2 (es) Polipéptidos que se enlazan a cxcr2
MX2011011508A (es) Vector genico.
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
AR077992A1 (es) Secuencia del genoma completo del metanogeno methanobrevibacter ruminantium
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
CL2012002250A1 (es) Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer.
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
IN2015DN03029A (es)
WO2011138328A3 (en) Use of inhibitory molecules for the treatment of pulmonary hypertension
BR112015021708A2 (pt) Inibidor de polipetídeo do tnfa, polinucleotídeo isolado, estrutura de expressão de ácido nucleico, célula de planta, composição farmacêutica e método de produção de um inibidor de polipeptídeo do tnfa
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
MX2014010698A (es) Polimeros cationicos con base en glucogeno.
WO2012065139A3 (en) Entpd5 inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure